José María Fernández Sousa-Faro, Ph.D.

President, Chief Executive Officer and Chairman of the Board

María Luisa de Francia Caballero

Chief Financial Officer

Belén Sopesén Veramendi, Ph.D.

Director, Market Research and Development

Luis Mora Capitán

Managing Director, Oncology Business Unit

Sebastián Cuenca Miranda

General Counsel and Secretary

José Luis Moreno Martinez-Losa

Director, Investor Relations & Capital Markets

Juan Carlos Villalón Gomez

Internal Auditor

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.